Remove Blogging Remove Invest Remove Presentation Remove San Diego

Biopharma Execs Remain Optimistic Despite Political Headwinds


These are among the major findings of a survey of 500 industry leaders and investors conducted by investment bank Jefferies. Drug pricing debates and uncertainty associated with Brexit are the issues most likely to keep biopharmaceutical executives awake at night.

Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone


In presenting clinical data from a Phase 3 study. Being first to market with a new type of drug brings advantages. The first mover sets the bar for what physicians, payers, and patients can expect of that medicine and how much it costs. It grabs market share that followers have to steal away.

Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More


jumped the presentation by a week, promising in a statement Monday that the data were very good, indeed. You might be camping, barbecuing, or sleeping on Monday. It’s Labor Day, after all. But in Paris, this cardiologist will be in a conference center, walking an audience through a slide deck packed with Phase 3 data for a new cholesterol-lowering drug, inclisiran. Inclisiran’s owner, the Medicines Co.,

California Accelerators Enroll Startups Targeting Cannabis Industry


On Monday, nine startups began a 16-week program at Canopy San Diego , a new accelerator program for seed-stage companies developing new technologies, products, and services to support the legal cannabis industry.

A16Z Bio Fund’s Pande Sees A.I. as Way to Ride Bio Innovation


As Andreessen Horowitz begins to invest the $450 million the bellwether venture firm recently raised for its second bio fund , general partner Vijay Pande has been talking increasingly about the use of artificial intelligence in the life sciences.

With $6M Investment, Histogen Aims to Grow Hair Business in China


Histogen, a San Diego-based regenerative medicine company with technology for growing skin cells and related products, said it has raised $6 million from an affiliate of Huapont Life Sciences, a healthcare products company based in Chongqing, China.

PacketSled Raises $5M for Automated Cybersecurity Monitoring System


PacketSled, a cybersecurity startup based in suburban San Diego, has raised $5 million in a Series A funding round led by Keshif Ventures, a local angel investment fund that has put money into dozens of tech startups in the San Diego area.

14 For ’17: Key Clinical Data to Watch For Next Year (Part 1)


After years of research, frustration, hype, and millions (sometimes hundreds of millions) of dollars invested, a drug program boils down to the clinical data—usually from big, late-stage studies—that can sometimes make or break a company. Biogen (NASDAQ: BIIB ) and Ionis Pharmaceuticals (NASDAQ: IONS ) presented data supporting what could become the first approved drug for spinal muscular atrophy.

Study 61

Biogen Buys Ionis Spine Disease Drug For $75M, Eyes FDA Filing


Neither company provided any specifics beyond the announcement, though Biogen said it will present the data in detail at a future medical meeting. Overall, 14 companies overall are investing in SMA programs, compared to zero in 2000, according to data from Cure SMA.

Study 83

Bio Roundup: Trump’s Triumph, Election Fallout, CRISPR Arguments & More


The Phase 3 results will be presented at a future medical meeting. —A month after Cambridge, MA-based Merrimack Pharmaceuticals (NASDAQ: MACK ) restructured and its CEO resigned , Reuters reported that the company has hired investment bankers to explore a possible sale. The presidential election ended with Donald Trump’s stunning victory and Republican retention of the House and Senate. Now, the U.S. healthcare sector will try to figure out what it all means.

Biotech Roundup: Biogen Rumors, Theranos, Electro-Drugs & More


That story and plenty more—including a bevy of gene therapy news, the latest on the Zika virus, and a long-awaited presentation from an embattled CEO—below: —Theranos CEO Elizabeth Holmes spoke at a conference for laboratory scientists this week in Philadelphia. —Meanwhile, scientists from San Diego-based Synthetic Genomics and the J. Biogen was once again all over the biotech newswire this week.

Brad Feld Drops Knowledge. Here’s What He Said …

Both Sides of the Table

I owe ya’ a 20 minute call (or in person next time I’m in San Diego). Brad on blogging. How did you start blogging? “My The value of Pitch Decks; Brad’s personal preferences on deal presentation; and Brad’s practice of accepting cold approaches via email.

SMTP 318

This Week in VC with Farb Nivi, Founder of Grockit

Both Sides of the Table

Went on to present at TechCrunch 50. And the broader question of whether VC’s will continue to invest in the Twitter ecosystem. Discussion: Had a long chat about PicClick , a company founded by Ryan Sit in San Diego.

S3 295

Tech Titans Peter Thiel, Matt Jacobson, Cameron and Tyler Winklevoss, Mich Mathews, Elon Musk Buy Homes in Los Angeles

SoCal Delicious

Developments Blog. To order presentation-ready copies for distribution to your colleagues, clients or customers, use the Order Reprints tool at the bottom of any article or visit MSN Money Investing. Downtown San Diego Condos. Investing Tools.

Silicon Beach Fest Celebrates Tech Startups and Hollywood in LA | Pics, Highlights and What’s Next!

Tech Zulu Event

If u see an article or write a blog post, email us or leave a comment below with a link to your story and we’ll add it in. Abbot Kinney Venice Blog: The New West Coast Digital & Creative Hubs: Venice and Santa Monica.